Health Care·Pharmaceuticals·$153.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.10 | N/A | -80.08% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.10 | N/A | -80.08% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current market environment and its impact on performance. They highlighted their commitment to improving operational efficiency.
Management acknowledged the challenging market conditions.
They emphasized a focus on cost management and operational efficiency.
Pfizer's earnings report indicates a significant miss on EPS, which contributed to a 3.22% decline in stock price. The lack of revenue data and guidance adds uncertainty for investors. Management's defensive tone suggests they are preparing for ongoing challenges in the market.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
NISOURCE INC
Feb 1, 2010